DocWire News Editors

DocwireNews

The Young Ophthalmologist Symposium at the American Academy of Ophthalmology 2020 Virtual meeting detailed some of the technological advancements that have occurred in 2020 driving changes in the future of ophthalmologic treatment paradigms. During the session, Raymond S. Douglas, MD, PhD, director of the Thyroid Eye Disease Program at Cedars Sinai, was asked to tell young ophthalmologists what they need to know about teprotumumab &ndash; which was approved in January 2020 for the treatment of thyroid eye disease (TED) &mdash; in a three-minute presentation.The inflammation and tissue remodeling associated with TED starts very early in the disease process and forms the basis of the clinical manifestations, Dr. Douglas explained. There is increased pressure in the fixed bony orbit from the short-term inflammation but also the long-term accumulation of hyaluronan and expansion of fibroblasts.TED is driven by autoantibody activation of the IGF-1 receptor.&ldquo;We know that the IGF-1 receptor is overexpressed in TED orbital fibroblasts and activation of this receptor stimulates the release of cytokines and the production of hyaluronan,&rdquo; Dr. Douglas said.Teprotumumab is a fully human monoclonal antibody inhibitor of the IGF1- receptor. It binds to the IGF1-recpetor and TSHR signaling complex. It halts the IGF-1 receptor and TSHR signaling at the TED source, reducing inflammation and reversing retro-orbital tissue expansion and hyaluronan production.Clinical studies of teprotumumab included a phase-2 and phase-3 study published in The New England Journal of Medicine. In these studies, teprotumumab demonstrated remarkable reduction on proptosis, reducing proptosis quickly, and, in most patients, achieving a reduction of greater than 2 mm proptosis at just two infusions. Eventually, the drug reduced proptosis by 3 mm compared with minimal change for placebo. The drug is administered over 8 infusions over 24 weeks with no further infusions unless there is a relapse.Imaging from the studies demonstrates improvement in muscle volume and fat stranding. This is in contrast to steroids, Dr. Douglas said, which do not generate any change in proptosis.Double vision was also greatly improved in patients receiving teprotumumab. Nearly 70% of patients had improvement of diplopia during this time period.The overall safety profile was good. The majority of treatment-emergent adverse events were mild to moderate and none led to treatment discontinuation.Finally, durability of teprotumumab was good. The majority of responders at 24 week retained response at week 72.

Bradley Marder, MD

Joel M. Topf, MD, FACP

Gout Studies: Transplant Waitlisting and Bone Erosion

NKF Spring Clinical Meetings 2025

Jayme Locke, MD, MPH

The Promise of Xenotransplantation

Leah Lawrence

Real-World Data Backs Invasive DFS as Surrogate Endpoint for OS in EBC

HR Breast Cancer

Latest News

Teprotumumab A Big Ophthalmologic Advance in 2020

AAO 2020

The Young Ophthalmologist Symposium at the American Academy of Ophthalmology 2020 Virtual meeting detailed some of the technological advancements that have occurred in 2020 ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe